Mortality Down With GLP-1 Receptor Agonist Use in T2D, Especially in Those With OSA
Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly lower one-year mortality, especially those also diagnosed with obstructive sleep apnea (OSA).
A study presented at CHEST 2025, the annual meeting of the American College of Chest Physicians, found that GLP-1 RAs reduce mortality in T2DM patients, particularly those with OSA.
- 1,799,261 patients with T2DM were identified and stratified into different groups.
- Patients with T2DM and OSA prescribed GLP-1 RAs had significantly lower one-year mortality.
According to the study, GLP-1 RAs have a positive effect on mortality in T2DM patients, especially those with OSA.
The study was conducted by Cosmo Fowler, M.D., from Emory University in Atlanta, and colleagues, using data from the TriNetX U.S. Collaborative Network.
Author's summary: GLP-1 RAs reduce mortality in T2DM patients with OSA.